{'fraction_non_alphanumeric': 0.030573248407643312, 'fraction_numerical': 0.016560509554140127, 'mean_word_length': 5.093023255813954, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
How could a drug used to treat alcoholism also be effective against glioblastoma?

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with dismal prognosis. Even after intervention with surgery, radiotherapy and chemotherapy, the overall survival of patients with GBM is only 42.4% at 6 months, 17.7% at 12 months and 3.3% at 2 years [1]. Currently available chemotherapy adds only marginal additional survival when combined with surgery and adjuvant radiotherapy. This is probably the result of both limited drug access because of the blood–brain barrier (BBB) and intrinsic resistance of GBM cells to many anticancer drugs. Therefore, development of new drugs that effectively penetrate the BBB and are toxic to GBM cells are urgently required.